# A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

> **NCT05441475** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 118 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w
- **DRUG:** ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg
- **DRUG:** ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg

## Key facts

- **NCT ID:** NCT05441475
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-12-30
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05441475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05441475, "A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05441475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*